Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2013-12-17 Major Shareholding Noti…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Share transactions with major shareholder 2 pages 119.0KB
Major Shareholding Notification Classification · 100% confidence The document is an ASX announcement dated 18 December 2013 regarding share transactions involving a major shareholder, Dr. Mervyn Jacobson, and entities associated with him. It details the disposal of a significant number of shares, a share exchange agreement, and related transactions affecting the ownership percentage of the major shareholder. The content focuses on changes in significant share ownership levels and the impact on the company's issued capital. There is no indication that this is a full financial report, earnings release, or management discussion. The document fits the definition of a Major Shareholding Notification, which involves notification of changes in significant share ownership levels crossing thresholds.
2013-12-17 English
Gtech International completes acquisition of Simavita 2 pages 110.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 12 December 2013 regarding the completion of an acquisition by Gtech International Resources Limited of Simavita Holdings. It details the transaction, share issuance, name change, and listing information. The content focuses on a corporate transaction and financing event, including capital raising through new shares and listing on exchanges. There is no detailed financial report, earnings data, or management discussion typical of annual or interim reports. The document is not a proxy, voting result, or legal proceeding update. It is a clear announcement of a capital transaction and acquisition completion, fitting the Capital/Financing Update category.
2013-12-11 English
Appointment of Dr. Paul Kasian 3 pages 39.9KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 12 December 2013 regarding the appointment of Dr. Paul Kasian as an Independent Non-Executive Director of Genetic Technologies Limited. It includes an Appendix 3X Initial Director's Interest Notice, which is a regulatory form disclosing the director's relevant interests in securities. The content focuses on management changes and director share interests, not on financial results, reports, or presentations. The document length is 4346 characters, which is relatively short and typical for a management change announcement. Therefore, the document fits the category of Board/Management Information (MANG).
2013-12-11 English
Publication of BREVAGen cost effectiveness study 2 pages 112.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 6 December 2013 from Genetic Technologies Limited. It discusses the publication of a study in the journal Cancer Prevention Research about the cost-effectiveness of their genetic breast cancer risk test, BREVAGen. The content is a press release highlighting the publication and its findings, not a financial report or regulatory filing. There are no financial statements, earnings data, or management discussion of financial results. The document is relatively short (6046 characters) and serves as an announcement of a scientific publication rather than a corporate financial or governance report. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2013-12-05 English
ASX Appendices 3X and 3Z 9 pages 61.6KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 4 December 2013, containing multiple Appendix 3X and 3Z forms. These forms are related to director interests notices: Appendix 3X is an Initial Director’s Interest Notice, and Appendix 3Z is a Final Director’s Interest Notice. The content details appointments and cessations of directors, their securities holdings, and interests in contracts. There is no financial data, earnings information, or report publication. The document is clearly about changes in the company's board of directors and their personal shareholdings disclosures. This matches the definition of Board/Management Information (MANG).
2013-12-03 English
2013 Annual General Meeting materials 19 pages 877.7KB
AGM Information Classification · 95% confidence The document is titled '2013 Annual General Meeting' and is described as a slide show presentation to be delivered at the company's 2013 AGM. It contains forward-looking statements, operational updates, sales force expansion, product development plans, licensing information, and fundraising activities. The content is consistent with materials typically presented at an AGM to shareholders, focusing on business updates and strategic direction rather than detailed financial statements or regulatory filings. The document is a presentation for the AGM, not the full annual report or other filings. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (7555 characters) supports it being a presentation rather than a brief announcement or a full report.
2013-11-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.